Advertisement
U.S. markets open in 1 hour 22 minutes

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6002-0.0598 (-9.06%)
At close: 04:00PM EDT
0.6002 0.00 (0.00%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close0.6600
Open0.6597
Bid0.5535 x 200
Ask0.6500 x 200
Day's Range0.5100 - 0.6863
52 Week Range0.1300 - 3.4600
Volume1,267,300
Avg. Volume975,800
Market Cap29.399M
Beta (5Y Monthly)0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCLI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Brainstorm Cell Therapeutics In
    CYTK: Raising target price to $75.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Zacks Small Cap Research

    BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3b Trial Design Announced; SPA Submitted to the FDA On March 4, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented a poster at the MDA Clinical and Scientific Conference with an outline of the proposed design for a Phase 3b trial of NurOwn® (debamestrocel) in amyotrophic lateral sclerosis (ALS).

  • PR Newswire

    BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#M201) outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS) at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida. The design is for a two-part, multicenter, Phase 3b study to assess the efficacy and safet

  • PR Newswire

    BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).